Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients,Journal of Neuroimmunology

当前位置： X-MOL 学术 › J. Neuroimmunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients
Journal of Neuroimmunology ( IF 2.9 ) Pub Date : 2020-11-01 , DOI: 10.1016/j.jneuroim.2020.577383
Huahua Zhong ₁ , Jun Lu ₁ , Sisi Jing ₂ , Jianying Xi ₁ , Chong Yan ₁ , Jie Song ₁ , Sushan Luo ₁ , Chongbo Zhao ₃

Affiliation

Two potentially related microRNAs (miRNAs; miR-150-5p and miR-146a-5p) were examined after low-dose rituximab (RTX) treatment in patients with acetylcholine receptor antibody (AChR)-positive refractory myasthenia gravis (MG). In this prospective, open-label, and self-controlled pilot trial, 12 AChR-positive refractory MG patients were administrated a single, low dose of RTX and followed up at six months. Results showed that RTX decreased the serum exosomal miR-150-5p, scores on three clinical indices (MGFA, MMT, ADL), and patients' prednisolone requirement. Additionally, CD19+ and CD27+ B cells decreased, showing a strong correlation with miR-150-5p. In conclusion, low-dose RTX is effective for AChR-positive refractory MG treatment. Furthermore, our data support the role of miR-150-5p as a potential biomarker for MG.

中文翻译：

低剂量利妥昔单抗降低 AChR 阳性难治性重症肌无力患者的血清外泌体 miR-150-5p

在乙酰胆碱受体抗体 (AChR) 阳性难治性重症肌无力 (MG) 患者接受低剂量利妥昔单抗 (RTX) 治疗后，检测了两种可能相关的微 RNA（miRNA；miR-150-5p 和 miR-146a-5p）。在这项前瞻性、开放标签和自我控制的试点试验中，12 名 AChR 阳性难治性 MG 患者接受了单次低剂量 RTX，并在 6 个月时进行了随访。结果表明，RTX 降低了血清外泌体 miR-150-5p、三个临床指标（MGFA、MMT、ADL）的评分以及患者对泼尼松龙的需求。此外，CD19+ 和 CD27+ B 细胞减少，显示出与 miR-150-5p 的强相关性。总之，低剂量 RTX 对 AChR 阳性难治性 MG 治疗有效。此外，我们的数据支持 miR-150-5p 作为 MG 的潜在生物标志物的作用。

更新日期：2020-11-01

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11